Close Menu
NEW YORK – Thermo Fisher Scientific said after the close of the market on Monday that it has priced an offering of $2.2 billion worth of senior notes.
 
The offering consists of $1.1 billion in senior notes with an interest rate of 4.133 percent due 2025 at the issue price of 100 percent of their principal amount; and $1.1 billion in senior notes with an interest rate of 4.97 percent due 2030 at the issue price of 100 percent of their principal amount.
 
The offering is expected to close on or about March 25, 2020, subject to customary closing condi

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.